BRCA1 and cancer: Notwithstanding the importance of PARP-1 in numerous pathways that govern genome integrity, the effective killing of HR-deficient BRCA1/2-mutated cancer cells by PARP inhibitors (PARPi) has been the basis for the development of therapies targeting breast and ovarian tumors (48,49).